Holen Sie sich die Stockscreener-App
8.42
6.13%
-0.55
Handel nachbörslich:
8.42
Schlusskurs vom Vortag:
$8.97
Offen:
$9
24-Stunden-Volumen:
792.89K
Relative Volume:
0.71
Marktkapitalisierung:
$577.90M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-96.66M
KGV:
-3.9163
EPS:
-2.15
Netto-Cashflow:
$-83.73M
1W Leistung:
-4.21%
1M Leistung:
-24.14%
6M Leistung:
+49.82%
1J Leistung:
-27.54%
1-Tages-Spanne:
$8.335
$9.24
1-Wochen-Bereich:
$8.335
$9.54
52-Wochen-Spanne:
$2.86
$13.51
Olema Pharmaceuticals Inc Stock (OLMA) Company Profile
Firmenname
Olema Pharmaceuticals Inc
Sektor
Branche
Telefon
(415) 651-3316
Adresse
780 BRANNAN STREET, SAN FRANCISCO
Vergleichen Sie OLMA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OLMA
Olema Pharmaceuticals Inc
|
8.42 | 615.65M | 0 | -96.66M | -83.73M | -2.15 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Olema Pharmaceuticals Inc Stock (OLMA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-08 | Eingeleitet | Guggenheim | Buy |
| 2025-08-12 | Bestätigt | Citigroup | Buy |
| 2024-04-02 | Eingeleitet | Goldman | Buy |
| 2024-01-30 | Eingeleitet | Citigroup | Buy |
| 2023-07-21 | Eingeleitet | Oppenheimer | Outperform |
| 2023-05-05 | Eingeleitet | CapitalOne | Overweight |
| 2023-02-22 | Eingeleitet | Credit Suisse | Outperform |
| 2022-07-06 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-06-09 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2022-02-28 | Eingeleitet | H.C. Wainwright | Neutral |
| 2021-12-07 | Fortgesetzt | Cowen | Outperform |
| 2020-12-14 | Eingeleitet | Canaccord Genuity | Buy |
| 2020-12-14 | Eingeleitet | Cowen | Outperform |
| 2020-12-14 | Eingeleitet | JP Morgan | Overweight |
| 2020-12-14 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Olema Pharmaceuticals Inc Aktie (OLMA) Neueste Nachrichten
Olema Oncology to Participate in Upcoming Investor Conferences - The Manila Times
Olema (NASDAQ: OLMA) to participate in Guggenheim, UBS and Jefferies conferences - Stock Titan
Will Olema Pharmaceuticals Inc. stock go up soonJuly 2025 Sentiment & Fast Momentum Entry Tips - newser.com
What Fibonacci levels say about Olema Pharmaceuticals Inc. rebound2025 Risk Factors & Growth Focused Investment Plans - newser.com
Forecasting Olema Pharmaceuticals Inc. price range with options dataEarnings Growth Report & Precise Swing Trade Entry Alerts - newser.com
Sector ETF performance correlation with Olema Pharmaceuticals Inc.Market Trend Report & AI Driven Price Forecasts - newser.com
Can Olema Pharmaceuticals Inc. stock double in next 5 yearsEarnings Growth Report & Free Fast Gain Swing Trade Alerts - newser.com
Why Olema Pharmaceuticals Inc. stock is in analyst buy zoneJuly 2025 Highlights & Real-Time Buy Signal Notifications - newser.com
Is Olema Pharmaceuticals Inc. stock ready for breakoutVolume Spike & Risk Managed Trade Strategies - newser.com
How sustainable is Olema Pharmaceuticals Inc. stock dividend payoutJuly 2025 Market Mood & Real-Time Chart Pattern Alerts - newser.com
How to build a dashboard for Olema Pharmaceuticals Inc. stockWeekly Stock Summary & Verified Momentum Stock Alerts - newser.com
Pier Capital LLC Has $3.29 Million Position in Olema Pharmaceuticals, Inc. $OLMA - MarketBeat
Why Olema Pharmaceuticals Inc. stock could rally in 2025July 2025 Price Swings & Verified Momentum Stock Alerts - newser.com
Olema Pharmaceuticals (NASDAQ:OLMA) Shares Gap UpHere's Why - MarketBeat
How geopolitical tensions affect Olema Pharmaceuticals Inc. stockRate Hike & Daily Growth Stock Investment Tips - newser.com
Olema Pharmaceuticals Inc. stock momentum explainedWeekly Stock Recap & Verified Entry Point Signals - newser.com
News impact scoring models applied to Olema Pharmaceuticals Inc.Bull Run & Free Long-Term Investment Growth Plans - newser.com
Will Olema Pharmaceuticals Inc. continue its uptrendGap Down & High Yield Equity Trading Tips - newser.com
Will Olema Pharmaceuticals Inc. stock rally after Fed decisions2025 Short Interest & Advanced Swing Trade Entry Plans - newser.com
Has Olema Pharmaceuticals Inc. found a price floorJuly 2025 Update & Trade Opportunity Analysis - newser.com
Olema Pharmaceuticals, Inc. (OLMA) stock price, news, quote and history - Yahoo! Finance UK
Olema Pharmaceuticals to Present Phase 3 OPERA-02 Trial Details at SABCS 2025 - Quiver Quantitative
Olema Oncology to Present Trial-in-Progress Poster for Phase 3 OPERA-02 Trial of Palazestrant Plus Ribociclib at SABCS 2025 - The Manila Times
Olema (NASDAQ: OLMA) to present OPERA-02 Phase 3 palazestrant + ribociclib at SABCS 2025 - Stock Titan
Finanzdaten der Olema Pharmaceuticals Inc-Aktie (OLMA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.64%
0.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):